Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy-Reference-Cited by-同舟云学术

Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy

Published:2018-10-18 Issue:2 Volume:98 Page:331-337
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Alkharabsheh Omar A.,Saadeh Salwa S.,Zblewski Darci L.,Gangat Naseema,Begna Kebede H.,Elliott Michelle A.,Alkhateeb Hassan B.,Patnaik Mrinal S.,Hogan William J.,Litzow Mark R.,Al-Kali Aref

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3509-0/fulltext.html

Reference29 articles.

1. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7):2292–2302

2. Celgene, Lenalidomide package insert

3. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R, Myelodysplastic Syndrome-003 Study Investigators (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355(14):1456–1465

4. List A et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352(6):549–557

5. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF (2008) Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111(1):86–93

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerebral venous thrombosis with myelodysplastic syndrome: a rare case report;2024-05-30

2. Thrombosis in Myeloid Malignancies: From CHIP to AML;Cardiovascular & Hematological Disorders-Drug Targets;2024-03

3. Practical aspects of the use of erythropoiesis-stimulating agent in patients with hematological malignancy;Meditsinskiy sovet = Medical Council;2022-10-06

4. Hemophagocytic Lymphohistiocytosis Secondary to Juvenile Myelomonocytic Leukemia;Journal of Pediatric Hematology/Oncology;2021-12-03

5. Isolated duodenal ischemia of unknown etiology: a case report;BMC Surgery;2021-12